4.6 Article

Detection of Somatic Mutations with ddPCR from Liquid Biopsy of Colorectal Cancer Patients

期刊

GENES
卷 12, 期 2, 页码 -

出版社

MDPI
DOI: 10.3390/genes12020289

关键词

colorectal cancer; liquid biopsy; cell-free DNA; somatic mutations; KRAS; BRAF; ddPCR; hemorrhoids

资金

  1. ddPCR Grant challenge initiative from Labena Ltd., Verovskova, Ljubljana, Slovenia
  2. Ministry of Education, Science, and Technological Development, Serbia [41033, 173008]
  3. COST Action [CA17118 TransColonCan]

向作者/读者索取更多资源

Liquid biopsy and cell-free DNA have great potential in cancer diagnostics, with a custom ddPCR assay designed for quantification of cfDNA in serum. The study validated the assay on CRC patients, hemorrhoid patients, and healthy controls, comparing mutation status in primary tumors and cfDNA isolated from serum. The findings suggest caution in interpreting decisions based solely on cfDNA levels in patient serum, and explore the potential of ddPCR somatic mutations detection from liquid biopsy as a supplement to tissue biopsy in personalized CRC patient management.
Liquid biopsy and cell-free DNA (cfDNA) show great promise in cancer diagnostics. In this study, we designed a custom droplet digital PCR (ddPCR) assay for the quantification and quality control of cfDNA isolated from serum. The assay was validated on a group of locally advanced colorectal cancer (CRC) patients and two control groups-patients with hemorrhoids and healthy individuals. The assay shows a high correlation with Qubit measurement (r = 0.976) but offers a higher dynamic range. Mean concentrations of cfDNA were 12.36 ng/mu L, 5.17 ng/mu L, and 0.29 ng/mu L for CRC, hemorrhoid patients, and healthy controls, respectively. The quality of cfDNA was assessed with the measurement of B-cell DNA contamination. On a subset of CRC patients, we compared the mutation status on KRAS (G12A, G12D, G12V, G13D) and BRAF (V600E) genes in the primary tumor and cfDNA isolated from the serum. A total of 70.6% of primary tumor samples were mutated, and the mean fractional abundance of mutations was 9.50%. The matching serum samples were mutated in 38% cases with an average fractional abundance of 0.23%. We conclude that any decisions based solely on the amount of cfDNA present in patient serum must be interpreted carefully and in the context of co-morbidities. This study explores the potential of ddPCR somatic mutations detection from liquid biopsy as a supplement to tissue biopsy in targeted personalized CRC patient management.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据